Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Teva’s Planned Mystery Generic Is Likely Lipitor, Bernstein Says

Teva Pharmaceutical Industries Ltd. may start selling a generic version of Pfizer Inc.’s Lipitor this quarter, Sanford C. Bernstein & Co. analysts said in an interpretation of the company’s comments about a large drug it failed to introduce earlier in the year.

“This is ostensibly Lipitor,” analysts led by Ronny Gal wrote in the report late yesterday. “What other product can give Teva 10 cents of earnings per share or $89 million net income in one month?”

Shir Altay, a spokeswoman for the Petach Tikva, Israel-based drugmaker, didn’t respond to telephone and e-mail requests for comment today. Teva said yesterday that if it manages to introduce the “important undisclosed product” in the fourth quarter, it would meet the upper range of its forecast of earnings excluding some costs of $4.92 to $5.02 a share this year.

Lipitor, the biggest product for New York-based Pfizer, is an anti-cholesterol pill.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.